



Supplement Figure 1

1A Subgroup analysis based on study design (DFS/RFS)




1C Subgroup analysis based on study design (EFS)




NOTE: Weights and between-subgroup heterogeneity test are from random-effects model

1B Subgroup analysis based on study design (OS)



1D Subgroup analysis based on study design (PFS)



NOTE: Weights and between-subgroup heterogeneity test are from random-effects model

Supplement Figure 1 - Forest plots of studies demonstrating the association between circulating tumor DNA positivity and survival outcomes in solid cancer patients who received neoadjuvant treatment across different study design. (A) Disease-free survival/recurrence-free survival in prospective cohort studies and randomized controlled trial. (B) Overall survival in prospective cohort studies, randomized controlled trial, and nonrandomized controlled trial. (C) Event-free survival in prospective cohort studies and randomized controlled trial. (D) Progression-free survival in prospective cohort studies, randomized controlled trial, and nonrandomized controlled trial. DFS/RFS, disease-free survival/recurrence-free survival; OS, overall survival; PFS, progression-free survival; EFS, event-free survival; HR, Hazard ratio; prospective, prospective cohort studies; rct, randomized controlled trial; non-rct, nonrandomized controlled trial.